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t
P
SPaclitaxel-Eluting Balloons for
Sirolimus-Eluting Stent Restenosis
We read with interest the randomized study by Habara et al. (1)
comparing paclitaxel-eluting balloon (PB) (n  25) with conven-
ional balloon (BA) (n  25) in patients suffering from sirolimus-
luting stent (SES) in-stent restenosis (ISR). In these patients, PB
rovided a dramatic improvement in angiographic parameters at
ate follow-up, compared with BA. This information is timely,
ecause ISR after drug-eluting stent (DES) implantation is be-
oming a growing concern due to the widespread use of DES in
ncreasingly complex anatomic scenarios (2). This study nicely
omplements a pioneer randomized trial where PB were also
trikingly superior to BA in patients with bare-metal ISR (3).
Actually, in-segment late angiographic loss after PB (0.03 mm)
was even lower than that found in the present study in SES ISR
(0.18 mm) (3). Considering the clinical implications of this small
yet provocative study, clarifying some methodological issues would
be of major practical value.
First, SES ISR frequently locates at the stent edges (4). In this
egard, data on the presence and implications of edge ISR with
espect to the relative efficacy of PB over BA would be of major
nterest (5). Second, SES underexpansion remains a frequent
rigger for subsequent ISR (6). Therefore, if available, intravascular
ltrasound data on the degree of stent expansion in these patients
ould be also of value. Likewise, information on inflation pres-
ures, both during pre-dilation and especially at final optimization,
ould be of great practical value, especially considering that
elatively low pressures are recommended with PB. Third, after
ES implantation, late angiographic findings (late loss, mini-
al lumen diameter, percentage diameter stenosis) usually do
ot follow a normal distribution (7). It would be of interest to
now whether similar angiographic distribution patterns are
een after PB.
The excellent results obtained with PB in the current study are
eassuring and open new venues in the management of patients
ith DES ISR. We fully agree (2) with the suggestion that further
tudies are warranted to confirm the efficacy of PB in ISR affecting
ther DES types and also to assess the relative value of PB versus
epeat DES implantation (i.e., RIBS IV [Restenosis Intrastent in
rug-eluting stents: paclitaxel-eluting Balloon versus everolimus-
luting Stent] randomized study) in this challenging anatomic
etting.
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Reply
We thank Dr. Alfonso and colleagues for their concern and
suggestions based on our recent publication (1). We appreciate
their suggestions and have performed the following analysis.
Focal restenosis occurs frequently at stent edges after drug-
eluting stent (DES) implantation (2). In the paclitaxel-eluting
balloon (PEB) group of our study, stent edge restenosis affected 3
of the 13 focal restenotic lesions. No recurrent restenosis occurred
in this group. We cannot conclude that PEB was effective for stent
edge restenosis, because of the small sample size in this study. We
believe stent edge restenosis should be handled carefully to not
cause coronary dissection.
Stent underexpansion is considered the cause of recurrent
restenosis (3). We did not have adequate intravascular ultrasound
data that could assess DES restenosis at the time of PEB use. In
our study, pre-dilation was performed with a noncompliant
balloon in all lesions. Pre-dilation pressure was higher in the
conventional balloon angioplasty group than in the PEB group
(21.4  3.7 atm vs. 19.2  6.4 atm; p  0.001). Balloon artery
ratio was similar (1.08  0.07 vs. 1.10  0.08; p  0.3) between
he groups. In the PEB group, inflation pressure for the SeQuent
lease balloon catheter (B. Braun Melsungen AG, Vascular
ystems, Berlin, Germany) was 13.0  2.4 atm. We believe thatobtaining a high acute gain and avoiding stent underexpansion by
